Research location
Mogilev
Belarus
Advertisement
Research activity in Mogilev
BelarusCureCurrent currently publishes aggregate city-level research activity for this location: 17 trials and 17 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Mogilev
17 linked trials · page 1 of 1A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaNCT05751928 · 2023-04-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaNCT05732805 · 2022-08-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)NCT04497844 · 2020-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03NCT04109391 · 2019-08-20 · 1 site observation
COMPLETED
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate CancerNCT03871816 · 2019-04-22 · 1 site observation
COMPLETED
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast CancerNCT03433313 · 2018-10-16 · 1 site observation
COMPLETED
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast CancerNCT03556358 · 2018-06-28 · 1 site observation
COMPLETED
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03088540 · 2017-05-29 · 1 site observation
COMPLETED
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)NCT03061812 · 2017-04-11 · 1 site observation
COMPLETED
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)NCT03033511 · 2017-02-07 · 1 site observation
TERMINATED
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLCNCT04633564 · 2017-01-21 · 1 site observation
COMPLETED
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung CancerNCT02754882 · 2016-07-05 · 1 site observation
COMPLETED
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung CancerNCT02106546 · 2014-04-10 · 1 site observation
COMPLETED
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast CancerNCT02163694 · 2014-04-08 · 1 site observation
COMPLETED
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsNCT02111564 · 2014-01-07 · 1 site observation
COMPLETED
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes AdultsNCT01103284 · 2010-04-01 · 1 site observation
COMPLETED
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung CancerNCT00805194 · 2008-12-03 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.